This study was conducted to assess the effect of carbamazepine, sodium valproate and phenytoin on serum liver enzymes in 49 epileptic patients admitted to the neurology outpatient clinic at Beni-Suef University between February 2010 and June 2011. The patients were separated into group I (16 patients) treated with 200-1200 mg/day carbamazepine; group II (16 patients) treated with 200-800 mg/day sodium valproate; and group III (17 patients) treated with 200-400 mg/day phenytoin. Serum liver enzymes aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) and serum level of antiepileptic drug were determined. No patient developed clinical symptoms of liver disease. Hepatic enzymes abnormal values were seen in 51.9 % (n=27) in the three study groups. In group I, the alterations at ALP enzyme were 50% (n=8). In group II, the alterations at ALT were 6.25% (n=1) and at ALP were 62.5% (n=10). In group III, the alterations at AST were 5.88% (n=1), at ALT were 17.65% (n=3) and at ALP were 23.53% (n=4). There was a statistically significant positive correlation between the dose/kg of carbamazepine and the serum level of the drug, a statistically significant positive correlation between the dose/kg of sodium valproate and AST and a statistically significant negative correlation between the duration of administration of sodium valproate and AST. There was also a statistically significant negative correlation between the duration of administration of carbamazepine and AST and ALP. In conclusion, sodium valproate was more hepatotoxic than carbamazepine which was more hepatotoxic than phenytoin. The routine screening of hepatic enzymes level during the chronic use of antiepileptic drugs is recommended.
Introduction
Epilepsy is not a disease, but a syndrome of different cerebral disorders of the Central Nervous System (CNS) which is characterized by excessive discharges of large numbers of neurons (Nikalje et al ., 2011) . It is very disabling condition, rendered especially disturbing because of its unpredictability and its being a common neurological disorder worldwide (Ahmad, 2011) .
The liver is the primary organ for drug metabolism and elimination for many antiepileptic drugs (AEDs) and thus is subjected to drug-induced toxicity. There is a wide range of hepatotoxic reactions, from mild and transient elevations of hepatic enzymes to fatal hepatic failure (Arroyo and de la Morena, 2001) .
Liver enzymes can serve as markers of hepatocellular injury e.g. aspartate aminotransferase (AST), alanine aminotransferase (ALT) or of an obstruction in the bile flow cholestasis e.g. alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT). Although these enzymes are elevated in liver disease, the elevation can also be secondary to enzyme induction without hepatic pathology (Ahmed and Siddiqi, 2006) . In particular, antiepileptic drugs have many serious reactions, as seen with carbamazepine (CBZ), valproic acid (VPA) and phenytoin (PHT). Though relatively rare, when compared with other consistently known hepatotoxic drugs, the hepatotoxicity induced by antiepileptic drug can lead to death or an acute liver failure which could imperatively require liver transplantation. The hepatotoxicity induced by antiepileptic drug occurs either because of production of reactive toxic metabolite/s or because of induction of immunoallergic reactions ( Lee, 2003; Bjornsson, 2008) . Such AEDs (CBZ, PHT and VPA) are associated with mild elevations of liver enzymes, which may occur in up to 50% of patients. These elevations are usually transitory or dose-related and do not appear to be associated with hepatocellular injury.
Usually, hepatotoxicity is associated with other clinical manifestations of drug allergy (fever, rash and eosinophilia). This reaction is typical of CBZ and PHT. Another idiosyncratic hepatotoxic reaction comes from hepatotoxic metabolites because of aberrant metabolism. This reaction has been observed with VPA (Arroyo and de la Morena, 2001) .
A more than two to threefold increase in liver enzymes during AED therapy should caution the physician of a potential of coexistent liver disease. If subsequent follow-up reveals a progressive increase in the values of the enzymes, investigations for coexistent liver disease are warranted and may require a switch to an alternative AED (Ahmed and Siddiqi, 2006) . Therefore the aim of the present work was to study the effect of antiepileptic drugs on liver enzymes.
Subjects and Methods Subjects
This study was conducted on 49 subjects selected from outpatient clinics at Beni-Suef University Hospital. In this crosssectional study, there were 3 groups of patients: Group I: included 16 epileptic patients on carbamazepine medication with daily dose ranging from 200 to 1200 mg. Group II: included 16 epileptic patients on sodium valproate medication with daily dose ranging from 200 to 800 mg. Group III: included 17 epileptic patients on phenytoin medication with daily dose ranging from 200 to 600 mg.
Inclusion criteria
The study included epileptic patients receiving one of the following antiepileptic drugs (carbamazepine, sodium valproate or phenytoin) from at least 6 months.
Exclusion criteria
Epileptic patients who had concomitant liver diseases, using other drugs causing elevation of liver enzymes (e.g. antibiotics, anti-rheumatic drugs, statins and nonsteroidal anti-inflammatory drugs) or those who were alcohol drinkers were excluded from the present study.
Methods
Subjects included in this study were submitted to the followings: Through clinical assessment Subjects included in this study were subjected to careful history taking, general and neurological examination" according to standardized neurological sheet" including the name, age, gender, weight of each epileptic patient, the duration of therapy and the daily dose of antiepileptic drug.
Laboratory Work up
All subjects included in this study were subjected after two hours of the antiepileptic drug's administration to the following laboratory investigations: 1) Serum liver enzymes including: a) Alanine aminotransferase (ALT) which has a reference range of 10-55U. b) Aspartate aminotransferase (AST) which has a reference range of 10-40 U/L. c) Alkaline phosphatase (ALP) which has a reference range of 45-115 U/L. 2) Serum level of the antiepileptic drug. a) Carbamazepine serum level which has a reference range of 4-12 µg/ml. b) Sodium valproate serum level which has a reference range of 50-100 µg/ml. c) Phenytoin serum level which has a reference range of 10-20 µg/ml. According to the reference range of either the antiepileptic drug's serum level or the liver enzymes serum level, the epileptic patients in each study group were classified into those with normal and those with abnormal serum level. Finally, the abnormal values of serum liver enzymes of each antiepileptic drug were compared with each other to rank these antiepileptic drugs according to their hepatotoxicity.
Results
Forty nine patients (22 females) completed the study in the three groups, 16 (7 females) in group I, 16 (8 females) in group II and 17 (7 females) in group III. The mean ± SD age of the epileptic patients in the three groups were 17.8 ± 14.4, 14.8 ± 10.5 and 31.8 ± 10.4, respectively. The serum level of antiepileptic drug in the three study groups is shown in Table 1 . The abnormal and normal values of liver enzymes for the epileptic patients in the three study groups are shown in Table 2 . There was a statistically significant difference between the three study groups as regards the mean values of ALP (p = 0.020), but there was no statistically significant difference between the study groups as regards the mean values of AST (p = 0.410) or ALT (p = 0.327). The results of the correlation between the duration of drug administration in years and liver enzymes are shown in Table 3 and Fig. 1-5 . In group I, there was a statistically significant negative correlation between the duration of administration of carbamazepine and AST (r coefficient = -0.5, p = 0.048) as shown in Fig. 1 . There was no significant correlation between the duration of drug administration and liver enzymes except between the AST and carbamazepine and sodium valproate and between ALP and carbamazepine as shown in Fig. 1-3 . The correlations were all negative correlation with correlation coefficient (r) = -0.5, -0.4 and -0.4 respectively and p = 0.048, 0.027 and 0.029, respectively. There was no statistically significant correlation between the duration of drug administration in years and the serum level of drug. Moreover, there was no statistically significant correlation between liver enzymes and the serum level of drug.
In group II, a statistically significant positive correlation between dose/kg of group II (sodium valproate) and AST (r coefficient = 0.7, p = 0.004) as shown in Fig.  4 . However, in groups I and III, there was no statistically significant correlation between dose/kg of the drug and any of the liver enzymes.
In group I, there was a statistically significant positive correlation between dose/kg of carbamazepine and Serum level of drug (r coefficient = 0.6, p = 0.010) as shown in Fig. 5 , but in groups II and III, there was no statistically significant correlation between dose/kg of the drug and the serum level of drug. 
Discussion
The present study was conducted on 49 epileptic patients; 16 patients using carbamazepine, 16 patients using sodium valproate and 17 patients using phenytoin. All patients were submitted to through history, medical and neurological examination, measurement of serum liver enzymes and serum level of antiepileptic drug. Patients using carbamazepine had significantly higher ALP than those using phenytoin, but there was no statistically significant difference between the three groups regarding AST or ALT. The results also revealed a statistically significant negative correlation between the duration of carbamazepine administration and AST & ALP.
In accordance with our results, (O'Hare et al ., 1980) (2007) reported there was no correlation between the duration of therapy of carbamazepine and elevated liver enzymes.
The results also show there was no statistically significant correlation between the daily dose of carbamazepine and liver enzymes. Similarly, Sillanpaa (1981) and Kalapos (2002) reported the hepatotoxicity of carbamazepine is independent of the daily dose. In contrast to our results Perucca et al . (2004) provided the data demonstrating a dose-dependent degree of enzyme induction in epileptic patients receiving therapeutic doses of carbamazepine.
The results also revealed there was no statistically significant correlation between the serum level of carbamazepine and liver enzymes. Contrary to our results, Deda (1993) reported a statistically significant positive relationship between the serum level of carbamazepine and the serum ALP level. Sonmez et al . (2006) illustrated that the discrepancy between the results can be attributed to patients' characteristics such as age, gender and race; differences in methods; and the study protocol. Also, the doses of carbamazepine might have been too low to cause significant elevations in liver enzymes levels.
Patients using sodium valproate have significantly higher ALP than those using phenytoin, but there was no statistically significant difference between the three groups regarding AST or ALT. The results also revealed a statistically significant positive correlation between the daily dose of sodium valproate and AST. In agreement with our study, Verma and Haidukewych (1994) showed a statistically significant correlation between the dose of valproic acid and AST. Moreover, Spiller et al . (2000) reported that valproic acid mediated hepatic injury is associated with dose dependent rise in serum liver enzymes. Contrary to our results, Sussman (1979) noted that valproic acid-associated hepatotoxicity is distinct from the form of dose-related liver enzyme elevation that appears to be reversible with a reduction in dosage or discontinuation of the drug. Moreover, Felker et al . (2003) and Willmore et al . (1978) demonstrated through retrospective studies a transient elevation of liver ALT and AST in epileptic patients on valproic acid. On the other hand, Hauser et al . (1996) found that these finding were not reproduced in a prospective study with a relatively small sample size.
The results of our study also reported a statistically significant negative correlation between the duration of sodium valproate administration and AST. Contrary to our findings, Huang et al . (2003) suggested that severe hepatotoxicity reaction may be unrelated to the dose or duration of valproic acid. Moreover, Huang et al . ( 2003) and Roma-Giannikou et al . (1999) proved that there was no statistically significant correlation between hepatotoxicity and the dose or duration of valproic acid. Similarly, Hoshino et al . (1995) suggested that there was no correlation between the elevations in ALT and AST and the dose of valproic acid. The results also indicated that there was no statistically significant correlation between the serum level of sodium valproate and liver enzymes.
Gopaul et al . (2003) and Sonmez et al . (2006) suggested that the divergence in results may be due to variations in risk factors of development of valproic acid induced hepatotoxicity e.g. younger age, mental retardation, history of metabolic disorders or inborn error of metabolism, polypharmacy, stressful condition such as infection and underlying liver disease. In addition, Boelsterli and Lim (2007) have recently proposed a unifying hypothesis that involves underlying genetic or acquired mitochondrial abnormalities as a major determinant of susceptibility to hepatotoxicity induced by valproic acid.
Patients using phenytoin have significantly lower ALP than those using carbamazepine or sodium valproate, but there was no statistically significant difference between the three groups regarding AST or ALT. Our results also revealed that there was no statistically significant correlation between the duration of phenytoin administration and liver enzymes, the dose of phenytoin and liver enzymes or between the serum level of phenytoin and liver enzymes. Similar to our findings, Craig (2005) found that there was no statistically significant correlation between serum level of phenytoin and the risk for hepatotoxicity. Controversially, Perucca et al . (2004) suggested a dosedependent degree of enzyme induction in epileptic patients receiving therapeutic doses of phenytoin. Similarly, Spielberg et al . (1981) proved a dose dependant hepatotoxicity of phenytoin. Moreover, Breckenridge (1973) and Ohnhaus et al . (1983) confirmed a statistically significant positive correlation between the dose of phenytoin and the serum liver enzymes. Similarly, Meythaler (1998) reported a statistically significant positive correlation between the dose of phenytoin and the serum alkaline phosphatase. Generally, Roy et al . (1993) suggested that chronic liver enzyme abnormalities associated with phenytoin have been attributed to enzyme induction. Similarly, Aiges et al . (1980) found that the transient nature of the elevations of ALT and AST, and the absence of specific histopathology during chronic treatment with phenytoin does not result in hepatotoxicity but rather in enzyme induction. Walia et al . (2004) reported that hepatotoxicity of phenytoin is an important side effect that has been brought to attention. Bessmertny et al . (2001) described the hepatotoxicity of phenytoin as antiepileptic hypersensitivity syndrome requiring immediate discontinuation of the antiepileptic drug.
According to Bauer and Blouin (1982) and Mendis et al . (1993) conflicting results may be due to the differences in age and sex.
The present study indicated that patients using carbamazepine have significantly higher ALP than those using phenytoin and patients using sodium valproate have significantly higher ALP than those using phenytoin. We also concluded that the more is the dose/kg of sodium valproate, the more is the elevation of AST, the more is the dose/kg of carbamazepine and the more is the serum level of carbamazepine. In addition, during the initiation of antiepileptic drugs, the liver enzymes were elevated due to the enzyme inducing property of some of them. That is what happened during the first 6 months of the administration of antiepileptic drug especially that our study was conducted on epileptic patients taking the antiepileptic drug from at least 6 months. But with time, the liver tests can normalize despite continued therapy probably due to adaptation in the liver. This idea was provided by Bjornsson (2008) .
Consequently, this thought explains the statistically significant negative correlation between the duration of the antiepileptic drug administration and AST and ALP. Finally, our results showed that sodium valproate is more hepatotoxic than carbamazepine which is more hepatotoxic than phenytoin. Routine screening of hepatic enzymes level during the chronic use of antiepileptic drugs is recommended. The need for obtaining baseline liver function tests is essential before starting antiepileptic therapy and regular monitoring of serum aminotransferase values that had any of the risk factors for liver damage during antiepileptic therapy. Precautions should be taken when using antiepileptic drugs in epileptic patients with pre-existing hepatic disorders, in patients using potentially hepatotoxic drugs or if signs or symptoms of hepatic impairment appear. Because little long-term hepatic follow-up is available with antiepileptic treatment, controlled studies in larger samples should be carried out to reveal the frequency and the risk factors of serious hepatotoxicity.
